Institution: Università degli Studi di Verona
Primary Field: Health (weighted toward more recent publications)
Scores use coauthorship adjustment: α/n credit per paper, where n = number of authors. α = 2.02: calibrated so average adjusted count equals average raw count (a zero-sum adjustment).
| Period | S (4x) | A (2x) | B (1x) | C (½x) | Total | Percentile |
|---|---|---|---|---|---|---|
| Last 5 Years | 0.00 | 0.00 | 0.67 | 0.00 | 0.67 | 22% |
| Last 10 Years | 0.00 | 0.00 | 3.53 | 0.00 | 3.53 | 61% |
| All Time | 0.00 | 0.00 | 5.21 | 0.00 | 5.21 | 82% |
| Year | Article | Journal | Tier | Authors |
|---|---|---|---|---|
| 2021 | R&D and market size: Who benefits from orphan drug legislation? | Journal of Health Economics | B | 3 |
| 2021 | A reply to “Who would benefit from average value‐based pricing?” | Health Economics | B | 2 |
| 2020 | The impact of managed entry agreements on pharmaceutical prices | Health Economics | B | 3 |
| 2020 | Which valued‐based price when patients are heterogeneous? | Health Economics | B | 2 |
| 2019 | Job sick leave: Detecting opportunistic behavior | Health Economics | B | 3 |
| 2016 | Late-stage pharmaceutical R&D and pricing policies under two-stage regulation | Journal of Health Economics | B | 4 |
| 2013 | Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective | Health Economics | B | 2 |
| 2012 | Static and dynamic efficiency of irreversible health care investments under alternative payment rules | Journal of Health Economics | B | 3 |